Tempest Therapeutics (NASDAQ: TPST), a clinical-stage biotechnology firm focused on innovative cancer therapies, announced a significant milestone on Thursday as it secured the U.S. Food and Drug Administration’s...
All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control
Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%.
Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week.
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.
Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development
President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets...
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing...